Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.38%
#3 Glidr Glidr +35.94%
#4 Walrus Walrus +22.68%
#5 Tutorial Tutorial +22.05%
#6 Codatta Codatta +16.69%
#7 Humanity Humanity +16.02%
#8 Ribbita by Virtuals Ribbita by Virtuals +14.73%
#9 Enso Enso +14.41%
#10 Cysic Cysic +12.50%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Rank in Stocks #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Share Price
$0.6
Last synced: 2024-08-14
Market Cap
$2.09M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
SG
Trade ASLAN Pharmaceuticals Limited (ASLN)

Category

Healthcare
Revenue for ASLAN Pharmaceuticals Limited (ASLN)
Revenue in Mar 2024 TTM: $12.00M
According to ASLAN Pharmaceuticals Limited latest financial reports the company's current revenue (TTM) is $12.00M. In 2022 the company made a revenue of 0.00 equal to the revenue in the year 2021 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for ASLAN Pharmaceuticals Limited from 2014 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $12.00M 0.00%
2023 $12.00M 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $3.00M 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 $11.49M 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 105,102.50%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 50,077.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 84,156.56%
BE